Zuellig Pharma
Concise Prescribing Info
Invasive aspergillosis; mucormycosis in patients for whom amphotericin B is inappropriate.
Dosage/Direction for Use
Recommended loading dose: 200 mg every 8 hr for 1st 48 hr. Maintenance dose: 200 mg once daily starting 12-24 hr after last loading dose.
May be taken with or without food: Swallow whole, do not chew/crush/dissolve/open cap.
Hypersensitivity. Patients w/ familial short QT syndrome. Co-administration w/ ketoconazole, high-dose ritonavir (>200 mg bd), strong CYP3A4/5 [eg, rifampicin, rifabutin, carbamazepine, long-acting barbiturates (eg, phenobarb), phenytoin, St. John's wort] or moderate CYP3A4/5 (eg, efavirenz, nafcillin, etravirine) inducers.
Special Precautions
Hypersensitivity to other azole antifungals. Discontinue use if severe cutaneous ARs eg, Stevens-Johnson syndrome develops. Hepatitis. Long-term use. Monitor hepatic enzymes as clinically indicated. Avoid co-administration w/ mild CYP3A4/5 inducers eg, aprepitant, prednisone, pioglitazone. Concomitant use w/ other medicinal products decreasing QT interval eg, rufinamide; strong CYP3A4/5 inhibitors; CYP3A4 substrates eg, tacrolimus, sirolimus or ciclosporin; CYP2B6 substrates eg, cyclophosphamide; P-gp substrates eg, digoxin, colchicine, dabigatran etexilate. May affect ability to drive & use machines. Not recommended in severe hepatic impairment (Child-Pugh C). Not recommended in women of childbearing potential not using contraception. Not to be used during pregnancy & lactation. Childn <18 yr. Elderly. Infusion: Discontinue use if infusion-related reactions occur. Not to be infused into same line or cannula concomitantly w/ other IV products.
Adverse Reactions
Hypokalaemia, decreased appetite; delirium; headache, somnolence; thrombophlebitis; dyspnoea, acute resp failure; vomiting, diarrhoea, nausea, abdominal pain; elevated liver chemistry tests; rash, pruritus; renal failure; chest pain, fatigue. Infusion: Inj site reaction.
Drug Interactions
Increased plasma conc w/ CYP3A4/5 inhibitors eg, ketoconazole, lopinavir/ritonavir, clarithromycin, indinavir, saquinavir, amprenavir, nelfinavir; esomeprazole. Decreased plasma conc w/ CYP3A4/5 inducers eg, rifampicin, rifabutin, carbamazepine, phenobarb, phenytoin, St. John's wort, efavirenz, nafcillin, etravirine, aprepitant, prednisone, pioglitazone, high-dose ritonavir (>200 mg bd). Increased plasma conc of CYP3A4/5 (eg, ciclosporin, sirolimus, tacrolimus, prednisone, short-acting opiates, statins, ethinyl oestradiol, norethindrone, midazolam), P-gp (eg, vinca alkaloids, dabigatran etexilate, digoxin, colchicine), BCRP (eg, methotrexate, daunorubicin, doxorubicin, imatinib, irinotecan, lapatinib, mitoxantrone, topotecan), OCT2 (eg, metformin) & UGT (eg, mycophenolate mofetil) substrates; dextromethorphan. Decreased plasma conc of CYP2B6 (eg, cyclophosphamide, delavirdine, nevaripine, bupropion) & CYP2C8 (eg, repaglinide) substrates; omeprazole.
MIMS Class
ATC Classification
J02AC05 - isavuconazole ; Belongs to the class of triazole derivatives. Used in the systemic treatment of mycotic infections.
Cresemba hard cap 100 mg
Cresemba infusion conc 200 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in